ArticlePloS one2016
Proteinuria during Follow-Up Period and Long-Term Renal Survival of Childhood IgA Nephropathy.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.Advances in therapy · 2025Pooled it
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.Pediatric nephrology (Berlin, Germany) · 2026Review
- IgA nephropathy new therapies: from data in adults to application in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- IgA Nephropathy in Native Kidneys: Oxford and Banff Classifications Reveal Distinct Profiles and Predict Outcomes in Pediatric and Adult Patients.Life (Basel, Switzerland) · 2025Article
- Modern Biomarkers in IgA Nephropathy and Their Potential in Paediatric Research.Journal of clinical medicine · 2025Review
- Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.Canadian journal of kidney health and disease · 2025Review
- Are children with IgA nephropathy different from adult patients?Pediatric nephrology (Berlin, Germany) · 2024Article
- Factors related to recurrence of proteinuria in childhood IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2024Article
- Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy.Pediatric research · 2023Article
- Validation of the children international IgA nephropathy prediction tool based on data in Southwest China.Frontiers in pediatrics · 2023Article
- Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathy.Renal failure · 2023Article
- New therapeutic perspectives for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2021Review
- Activation of fibroblast growth factor-inducible 14 in the early phase of childhood IgA nephropathy.PloS one · 2021Article
- The implications of focal segmental glomerulosclerosis in children with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2020Review
- Clinical and histological differences between adults and children in new onset IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2020Article
- Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases.Scientific reports · 2020Article
- Risk factor for persistent proteinuria in adulthood after clinical remission in Japanese children with immunoglobulin A nephropathy: impact of tonsillectomy combined with intravenous pulse methylprednisolone.Clinical and experimental nephrology · 2020Article
- Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.Frontiers in pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProteinuria is the most important risk factor for IgA nephropathy progression. The purpose of this study is to evaluate the long-term outcome and risk factors for poor prognosis in childhood IgA nephropathy.
methodsPatients who were diagnosed with IgA nephropathy between 1972 and 1992 at the Tokyo Metropolitan Kiyose Children's Hospital were included. We analyzed risk factors for progression to end-stage kidney disease (ESKD) and chronic renal insufficiency (CRI) using Kaplan-Meier method and multivariate analyses of Cox proportional hazard model.
resultsOne hundred patients were included and the median observation period was 11.8 years. Twelve and 17 patients progressed to ESKD and CRI, respectively. The survival probabilities were 90.0% at 10 years and 79.8% at 20 years for ESKD, and 86.1% at 10 years and 72.3% at 20 years for CRI. Notably, patients with heavy proteinuria with hypoalbuminemia during follow-up period showed extremely poor prognosis. In this group, the survival rate at 10 years from ESKD and CRI was 40.6% and 20.8%, respectively. By multivariate analysis, proteinuria at diagnosis and proteinuria during follow-up period were risk factors for ESKD, whereas glomeruli showing mesangial proliferation ≥50% and proteinuria during follow-up period were risk factors for CRI. Patients without heavy proteinuria during follow-up period did not develop CRI and 63% of patients with mild proteinuria during follow-up period showed no proteinuria at the last observation.
conclusionsThe degree of proteinuria during follow-up period is the strongest risk factor for ESKD and CRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.